Immutep Ltd (NASDAQ:IMMP)

1.84
Delayed Data
As of Apr 24
 0.00 / 0.00%
Today’s Change
1.25
Today|||52-Week Range
2.85
+17.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$43.9M

Company Description

Immutep Ltd. is a biotechnology company, which engages in developing immunotherapeutic products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Contact Information

Immutep Ltd.
95 Pitt Street
Sydney New South Wales (nsw) 2000
P:(129) 276-1224
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Marc VoigtChief Executive Officer, CFO & Executive Director
Deanne MillerCOO, Secretary & General Counsel
Frédéric TriebelChief Scientific & Medical Officer
Christian MuellerDirector-Clinical Development
Jay R. CampbellVP-Business Development & Investor Relations